CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT01613768
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:37:08.377673+00:00
- Published At
- 2018-08-10T00:00:00+00:00
- Record Updated At
- 2018-09-28
- Results Posted At
- 2018-08-10
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Recurrent Salivary Gland Cancer", "Stage IVA Salivary Gland Cancer", "Stage IVB Salivary Gland Cancer", "Stage IVC Salivary Gland Cancer"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-09-28"- protocolSection.identificationModule.nctId
"NCT01613768"- protocolSection.identificationModule.officialTitle
"Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2018-08-10"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.